{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T17:48:00Z","timestamp":1777398480114,"version":"3.51.4"},"reference-count":68,"publisher":"The Editorial Committee of Annals of Vascular Diseases","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Annals of Vascular Diseases","Ann Vasc Dis","AVD"],"published-print":{"date-parts":[[2023,3,25]]},"DOI":"10.3400\/avd.ra.23-00003","type":"journal-article","created":{"date-parts":[[2023,3,6]],"date-time":"2023-03-06T22:10:37Z","timestamp":1678140637000},"page":"8-16","source":"Crossref","is-referenced-by-count":12,"title":["Complexity of Inflammation in the Trajectory of Vascular Disease: Interleukin 6 and Beyond"],"prefix":"10.3400","volume":"16","author":[{"given":"Motoaki","family":"Sano","sequence":"first","affiliation":[{"name":"Department of Cardiology, Keio University School of Medicine"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1983","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"1) Ridker PM, Danielson E, Fonseca FA, et al. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med 2008; <b>359<\/b>: 2195-207.","DOI":"10.1056\/NEJMoa0807646"},{"key":"2","doi-asserted-by":"crossref","unstructured":"2) Ridker PM, Everett BM, Thuren T, et al. Antiinflammatory therapy with canakinumab for atherosclerotic disease. N Engl J Med 2017; <b>377<\/b>: 1119-31.","DOI":"10.1056\/NEJMoa1707914"},{"key":"3","unstructured":"3) Ridker PM, MacFadyen JG, Thuren T, et al. Effect of interleukin-1beta inhibition with canakinumab on incident lung cancer in patients with atherosclerosis: exploratory results from a randomised, double-blind, placebo-controlled trial. Lancet 2017; <b>390<\/b>: 1833-42."},{"key":"4","doi-asserted-by":"crossref","unstructured":"4) Duewell P, Kono H, Rayner KJ, et al. NLRP3 inflammasomes are required for atherogenesis and activated by cholesterol crystals. Nature 2010; <b>464<\/b>: 1357-61.","DOI":"10.1038\/nature08938"},{"key":"5","doi-asserted-by":"crossref","unstructured":"5) Strandberg TE, Kovanen PT. Coronary artery disease: \u2018gout\u2019 in the artery? Eur Heart J 2021; <b>42<\/b>: 2761-4.","DOI":"10.1093\/eurheartj\/ehab276"},{"key":"6","doi-asserted-by":"crossref","unstructured":"6) Kutikhin AG, Feenstra L, Kostyunin AE, et al. Calciprotein particles: balancing mineral homeostasis and vascular pathology. Arterioscler Thromb Vasc Biol 2021; <b>41<\/b>: 1607-24.","DOI":"10.1161\/ATVBAHA.120.315697"},{"key":"7","unstructured":"7) Nidorf SM, Fiolet ATL, Mosterd A, et al. Colchicine in patients with chronic coronary disease. N Engl J Med 2020; <b>383<\/b>: 1838-47."},{"key":"8","doi-asserted-by":"crossref","unstructured":"8) Tardif JC, Kouz S, Waters DD, et al. Efficacy and safety of low-dose colchicine after myocardial infarction. N Engl J Med 2019; <b>381<\/b>: 2497-505.","DOI":"10.1056\/NEJMoa1912388"},{"key":"9","doi-asserted-by":"crossref","unstructured":"9) Opstal TSJ, Hoogeveen RM, Fiolet ATL, et al. Colchicine attenuates inflammation beyond the inflammasome in chronic coronary artery disease: a LoDoCo2 proteomic substudy. Circulation 2020; <b>142<\/b>: 1996-8.","DOI":"10.1161\/CIRCULATIONAHA.120.050560"},{"key":"10","doi-asserted-by":"crossref","unstructured":"10) Ridker PM, Rane M. Interleukin-6 signaling and anti-interleukin-6 therapeutics in cardiovascular disease. Circ Res 2021; <b>128<\/b>: 1728-46.","DOI":"10.1161\/CIRCRESAHA.121.319077"},{"key":"11","doi-asserted-by":"crossref","unstructured":"11) Kishimoto T. IL-6: from its discovery to clinical applications. Int Immunol 2010; <b>22<\/b>: 347-52.","DOI":"10.1093\/intimm\/dxq030"},{"key":"12","doi-asserted-by":"crossref","unstructured":"12) Rose-John S, Neurath MF. IL-6 trans-signaling: the heat is on. Immunity 2004; <b>20<\/b>: 2-4.","DOI":"10.1016\/S1074-7613(04)00003-2"},{"key":"13","doi-asserted-by":"crossref","unstructured":"13) Ridker PM, Devalaraja M, Baeres FMM, et al. IL-6 inhibition with ziltivekimab in patients at high atherosclerotic risk (RESCUE): a double-blind, randomised, placebo-controlled, phase 2 trial. Lancet 2021; <b>397<\/b>: 2060-9.","DOI":"10.1016\/S0140-6736(21)00520-1"},{"key":"14","doi-asserted-by":"crossref","unstructured":"14) Tanaka K, Watanabe T, Takeuchi A, et al. Cardiovascular events and death in Japanese patients with chronic kidney disease. Kidney Int 2017; <b>91<\/b>: 227-34.","DOI":"10.1016\/j.kint.2016.09.015"},{"key":"15","doi-asserted-by":"crossref","unstructured":"15) Sakakura K, Kubo N, Ako J, et al. Peak C-reactive protein level predicts long-term outcomes in type B acute aortic dissection. Hypertension 2010; <b>55<\/b>: 422-9.","DOI":"10.1161\/HYPERTENSIONAHA.109.143131"},{"key":"16","doi-asserted-by":"crossref","unstructured":"16) Kurihara T, Shimizu-Hirota R, Shimoda M, et al. Neutrophil-derived matrix metalloproteinase 9 triggers acute aortic dissection. Circulation 2012; <b>126<\/b>: 3070-80.","DOI":"10.1161\/CIRCULATIONAHA.112.097097"},{"key":"17","doi-asserted-by":"crossref","unstructured":"17) Anzai A, Shimoda M, Endo J, et al. Adventitial CXCL1\/G-CSF expression in response to acute aortic dissection triggers local neutrophil recruitment and activation leading to aortic rupture. Circ Res 2015; <b>116<\/b>: 612-23.","DOI":"10.1161\/CIRCRESAHA.116.304918"},{"key":"18","doi-asserted-by":"crossref","unstructured":"18) Nakaoka Y, Isobe M, Takei S, et al. Efficacy and safety of tocilizumab in patients with refractory Takayasu arteritis: results from a randomised, double-blind, placebo-controlled, phase 3 trial in Japan (the TAKT study). Ann Rheum Dis 2018; <b>77<\/b>: 348-54.","DOI":"10.1136\/annrheumdis-2017-211878"},{"key":"19","doi-asserted-by":"crossref","unstructured":"19) Nakaoka Y, Isobe M, Tanaka Y, et al. Long-term efficacy and safety of tocilizumab in refractory Takayasu arteritis: final results of the randomized controlled phase 3 TAKT study. Rheumatology (Oxford) 2020; <b>59<\/b>: 2427-34.","DOI":"10.1093\/rheumatology\/kez630"},{"key":"20","doi-asserted-by":"crossref","unstructured":"20) Nakaoka Y, Yanagawa M, Hata A, et al. Vascular imaging of patients with refractory Takayasu arteritis treated with tocilizumab: post hoc analysis of a randomized controlled trial. Rheumatology (Oxford) 2022; <b>61<\/b>: 2360-8.","DOI":"10.1093\/rheumatology\/keab684"},{"key":"21","doi-asserted-by":"crossref","unstructured":"21) Harigai M, Miyamae T, Hashimoto H, et al. A multicentre, large-scale, observational study of tocilizumab in patients with Takayasu arteritis in Japan: the ACT-Bridge study. Mod Rheumatol 2022; roac099.","DOI":"10.1093\/mr\/roac099"},{"key":"22","doi-asserted-by":"crossref","unstructured":"22) Muratore F, Salvarani C. Aortic dilatation in a patient with Takayasu arteritis treated with tocilizumab. Ann Rheum Dis 2021; <b>80<\/b>: e121.","DOI":"10.1136\/annrheumdis-2019-215459"},{"key":"23","doi-asserted-by":"crossref","unstructured":"23) Sanchez-Alvarez C, Koster M, Duarte-Garc\u00eda A, et al. Disease progression of Takayasu arteritis in two patients treated with tocilizumab. Ann Rheum Dis 2020; <b>79<\/b>: e21.","DOI":"10.1136\/annrheumdis-2018-214642"},{"key":"24","doi-asserted-by":"crossref","unstructured":"24) Lok ZSY, Lyle AN. Osteopontin in vascular disease. Arterioscler Thromb Vasc Biol 2019; <b>39<\/b>: 613-22.","DOI":"10.1161\/ATVBAHA.118.311577"},{"key":"25","doi-asserted-by":"crossref","unstructured":"25) Shirakawa K, Sano M. Osteopontin in cardiovascular diseases. Biomolecules 2021; <b>11<\/b>: 1047.","DOI":"10.3390\/biom11071047"},{"key":"26","doi-asserted-by":"crossref","unstructured":"26) Shirakawa K, Endo J, Kataoka M, et al. IL (interleukin)-10-STAT3-galectin-3 axis is essential for osteopontin-producing reparative macrophage polarization after myocardial infarction. Circulation 2018; <b>138<\/b>: 2021-35.","DOI":"10.1161\/CIRCULATIONAHA.118.035047"},{"key":"27","doi-asserted-by":"crossref","unstructured":"27) Singh K, Sirokman G, Communal C, et al. Myocardial osteopontin expression coincides with the development of heart failure. Hypertension 1999; <b>33<\/b>: 663-70.","DOI":"10.1161\/01.HYP.33.2.663"},{"key":"28","doi-asserted-by":"crossref","unstructured":"28) Abdalrhim AD, Marroush TS, Austin EE, et al. Plasma osteopontin levels and adverse cardiovascular outcomes in the PEACE trial. PLoS One 2016; <b>11<\/b>: e0156965.","DOI":"10.1371\/journal.pone.0156965"},{"key":"29","doi-asserted-by":"crossref","unstructured":"29) Carbone F, Rigamonti F, Burger F, et al. Serum levels of osteopontin predict major adverse cardiovascular events in patients with severe carotid artery stenosis. Int J Cardiol 2018; <b>255<\/b>: 195-9.","DOI":"10.1016\/j.ijcard.2018.01.008"},{"key":"30","doi-asserted-by":"crossref","unstructured":"30) Ikeda T, Shirasawa T, Esaki Y, et al. Osteopontin mRNA is expressed by smooth muscle-derived foam cells in human atherosclerotic lesions of the aorta. J Clin Invest 1993; <b>92<\/b>: 2814-20.","DOI":"10.1172\/JCI116901"},{"key":"31","doi-asserted-by":"crossref","unstructured":"31) Strobescu-Ciobanu C, Giu\u015fc\u0103 SE, C\u0103runtu ID, et al. Osteopontin and osteoprotegerin in atherosclerotic plaque - are they significant markers of plaque vulnerability? Rom J Morphol Embryol 2020; <b>61<\/b>: 793-801.","DOI":"10.47162\/RJME.61.3.17"},{"key":"32","doi-asserted-by":"crossref","unstructured":"32) Mazzone A, Parri MS, Giannessi D, et al. Osteopontin plasma levels and accelerated atherosclerosis in patients with CAD undergoing PCI: a prospective clinical study. Coron Artery Dis 2011; <b>22<\/b>: 179-87.","DOI":"10.1097\/MCA.0b013e3283441d0b"},{"key":"33","doi-asserted-by":"crossref","unstructured":"33) Isoda K, Kamezawa Y, Ayaori M, et al. Osteopontin transgenic mice fed a high-cholesterol diet develop early fatty-streak lesions. Circulation 2003; <b>107<\/b>: 679-81.","DOI":"10.1161\/01.CIR.0000055739.13639.D7"},{"key":"34","doi-asserted-by":"crossref","unstructured":"34) Matsui Y, Rittling SR, Okamoto H, et al. Osteopontin deficiency attenuates atherosclerosis in female apolipoprotein E-deficient mice. Arterioscler Thromb Vasc Biol 2003; <b>23<\/b>: 1029-34.","DOI":"10.1161\/01.ATV.0000074878.29805.D0"},{"key":"35","doi-asserted-by":"crossref","unstructured":"35) Speer MY, Chien YC, Quan M, et al. Smooth muscle cells deficient in osteopontin have enhanced susceptibility to calcification in vitro. Cardiovasc Res 2005; <b>66<\/b>: 324-33.","DOI":"10.1016\/j.cardiores.2005.01.023"},{"key":"36","doi-asserted-by":"crossref","unstructured":"36) Speer MY, McKee MD, Guldberg RE, et al. Inactivation of the osteopontin gene enhances vascular calcification of matrix Gla protein-deficient mice: evidence for osteopontin as an inducible inhibitor of vascular calcification in vivo. J Exp Med 2002; <b>196<\/b>: 1047-55.","DOI":"10.1084\/jem.20020911"},{"key":"37","doi-asserted-by":"crossref","unstructured":"37) Steitz SA, Speer MY, McKee MD, et al. Osteopontin inhibits mineral deposition and promotes regression of ectopic calcification. Am J Pathol 2002; <b>161<\/b>: 2035-46.","DOI":"10.1016\/S0002-9440(10)64482-3"},{"key":"38","doi-asserted-by":"crossref","unstructured":"38) Jono S, Peinado C, Giachelli CM. Phosphorylation of osteopontin is required for inhibition of vascular smooth muscle cell calcification. J Biol Chem 2000; <b>275<\/b>: 20197-203.","DOI":"10.1074\/jbc.M909174199"},{"key":"39","doi-asserted-by":"crossref","unstructured":"39) Shirakawa K, Endo J, Katsumata Y, et al. Negative legacy of obesity. PLoS One 2017; <b>12<\/b>: e0186303.","DOI":"10.1371\/journal.pone.0186303"},{"key":"40","doi-asserted-by":"crossref","unstructured":"40) Shirakawa K, Yan X, Shinmura K, et al. Obesity accelerates T cell senescence in murine visceral adipose tissue. J Clin Invest 2016; <b>126<\/b>: 4626-39.","DOI":"10.1172\/JCI88606"},{"key":"41","doi-asserted-by":"crossref","unstructured":"41) Ronco C, Haapio M, House AA, et al. Cardiorenal syndrome. J Am Coll Cardiol 2008; <b>52<\/b>: 1527-39.","DOI":"10.1016\/j.jacc.2008.07.051"},{"key":"42","doi-asserted-by":"crossref","unstructured":"42) Yan X, Sano M, Lu L, et al. Plasma concentrations of osteopontin, but not thrombin-cleaved osteopontin, are associated with the presence and severity of nephropathy and coronary artery disease in patients with type 2 diabetes mellitus. Cardiovasc Diabetol 2010; <b>9<\/b>: 70.","DOI":"10.1186\/1475-2840-9-70"},{"key":"43","doi-asserted-by":"crossref","unstructured":"43) Sano M. A new class of drugs for heart failure: SGLT2 inhibitors reduce sympathetic overactivity. J Cardiol 2018; <b>71<\/b>: 471-6.","DOI":"10.1016\/j.jjcc.2017.12.004"},{"key":"44","doi-asserted-by":"crossref","unstructured":"44) Sano M. A Paradigm shift in the treatment of type 2 diabetes and heart failure. J Atheroscler Thromb 2020; <b>27<\/b>: 727-31.","DOI":"10.5551\/jat.RV17042"},{"key":"45","doi-asserted-by":"crossref","unstructured":"45) Sano M. Inter-organ communication pathway manifested by non-physiological stress to the kidney in type II diabetic patients -why are diabetic patients prone to develop heart failure? Intern Med 2020; <b>59<\/b>: 1-5.","DOI":"10.2169\/internalmedicine.2870-19"},{"key":"46","doi-asserted-by":"crossref","unstructured":"46) Sano M, Goto S. Possible mechanism of hematocrit elevation by sodium glucose cotransporter 2 inhibitors and associated beneficial renal and cardiovascular effects. Circulation 2019; <b>139<\/b>: 1985-7.","DOI":"10.1161\/CIRCULATIONAHA.118.038881"},{"key":"47","doi-asserted-by":"crossref","unstructured":"47) Sas KM, Kayampilly P, Byun J, et al. Tissue-specific metabolic reprogramming drives nutrient flux in diabetic complications. JCI Insight 2016; <b>1<\/b>: e86976.","DOI":"10.1172\/jci.insight.86976"},{"key":"48","doi-asserted-by":"crossref","unstructured":"48) Li J, Liu H, Takagi S, et al. Renal protective effects of empagliflozin via inhibition of EMT and aberrant glycolysis in proximal tubules. JCI Insight 2020; <b>5<\/b>: e129034.","DOI":"10.1172\/jci.insight.129034"},{"key":"49","doi-asserted-by":"crossref","unstructured":"49) Shirakawa K, Sano M. Sodium-glucose co-transporter 2 inhibitors correct metabolic maladaptation of proximal tubular epithelial cells in high-glucose conditions. Int J Mol Sci 2020; <b>21<\/b>: 7676.","DOI":"10.3390\/ijms21207676"},{"key":"50","doi-asserted-by":"crossref","unstructured":"50) Brinkmann V, Reichard U, Goosmann C, et al. Neutrophil extracellular traps kill bacteria. Science 2004; <b>303<\/b>: 1532-5.","DOI":"10.1126\/science.1092385"},{"key":"51","doi-asserted-by":"crossref","unstructured":"51) Papayannopoulos V. Neutrophil extracellular traps in immunity and disease. Nat Rev Immunol 2018; <b>18<\/b>: 134-47.","DOI":"10.1038\/nri.2017.105"},{"key":"52","doi-asserted-by":"crossref","unstructured":"52) Menegazzo L, Ciciliot S, Poncina N, et al. NETosis is induced by high glucose and associated with type 2 diabetes. Acta Diabetol 2015; <b>52<\/b>: 497-503.","DOI":"10.1007\/s00592-014-0676-x"},{"key":"53","doi-asserted-by":"crossref","unstructured":"53) Wang L, Zhou X, Yin Y, et al. Hyperglycemia induces neutrophil extracellular traps formation through an NADPH oxidase-dependent pathway in diabetic retinopathy. Front Immunol 2018; <b>9<\/b>: 3076.","DOI":"10.3389\/fimmu.2018.03076"},{"key":"54","doi-asserted-by":"crossref","unstructured":"54) Metzler KD, Fuchs TA, Nauseef WM, et al. Myeloperoxidase is required for neutrophil extracellular trap formation: implications for innate immunity. Blood 2011; <b>117<\/b>: 953-9.","DOI":"10.1182\/blood-2010-06-290171"},{"key":"55","doi-asserted-by":"crossref","unstructured":"55) Papayannopoulos V, Metzler KD, Hakkim A, et al. Neutrophil elastase and myeloperoxidase regulate the formation of neutrophil extracellular traps. J Cell Biol 2010; <b>191<\/b>: 677-91.","DOI":"10.1083\/jcb.201006052"},{"key":"56","doi-asserted-by":"crossref","unstructured":"56) Kahlenberg JM, Carmona-Rivera C, Smith CK, et al. Neutrophil extracellular trap-associated protein activation of the NLRP3 inflammasome is enhanced in lupus macrophages. J Immunol 2013; <b>190<\/b>: 1217-26.","DOI":"10.4049\/jimmunol.1202388"},{"key":"57","doi-asserted-by":"crossref","unstructured":"57) Wilson AS, Randall KL, Pettitt JA, et al. Neutrophil extracellular traps and their histones promote Th17 cell differentiation directly via TLR2. Nat Commun 2022; <b>13<\/b>: 528.","DOI":"10.1038\/s41467-022-28172-4"},{"key":"58","doi-asserted-by":"crossref","unstructured":"58) Warnatsch A, Ioannou M, Wang Q, et al. Inflammation. Neutrophil extracellular traps license macrophages for cytokine production in atherosclerosis. Science 2015; <b>349<\/b>: 316-20.","DOI":"10.1126\/science.aaa8064"},{"key":"59","doi-asserted-by":"crossref","unstructured":"59) Fahed AC, Jang IK. Plaque erosion and acute coronary syndromes: phenotype, molecular characteristics and future directions. Nat Rev Cardiol 2021; <b>18<\/b>: 724-34.","DOI":"10.1038\/s41569-021-00542-3"},{"key":"60","doi-asserted-by":"crossref","unstructured":"60) Franck G, Mawson TL, Folco EJ, et al. Roles of PAD4 and NETosis in experimental atherosclerosis and arterial injury: implications for superficial erosion. Circ Res 2018; <b>123<\/b>: 33-42.","DOI":"10.1161\/CIRCRESAHA.117.312494"},{"key":"61","doi-asserted-by":"crossref","unstructured":"61) Quillard T, Ara\u00fajo HA, Franck G, et al. TLR2 and neutrophils potentiate endothelial stress, apoptosis and detachment: implications for superficial erosion. Eur Heart J 2015; <b>36<\/b>: 1394-404.","DOI":"10.1093\/eurheartj\/ehv044"},{"key":"62","doi-asserted-by":"crossref","unstructured":"62) Stakos DA, Kambas K, Konstantinidis T, et al. Expression of functional tissue factor by neutrophil extracellular traps in culprit artery of acute myocardial infarction. Eur Heart J 2015; <b>36<\/b>: 1405-14.","DOI":"10.1093\/eurheartj\/ehv007"},{"key":"63","doi-asserted-by":"crossref","unstructured":"63) Hayashida K, Sano M, Kamimura N, et al. Hydrogen inhalation during normoxic resuscitation improves neurological outcome in a rat model of cardiac arrest independently of targeted temperature management. Circulation 2014; <b>130<\/b>: 2173-80.","DOI":"10.1161\/CIRCULATIONAHA.114.011848"},{"key":"64","doi-asserted-by":"crossref","unstructured":"64) Hayashida K, Sano M, Ohsawa I, et al. Inhalation of hydrogen gas reduces infarct size in the rat model of myocardial ischemia-reperfusion injury. Biochem Biophys Res Commun 2008; <b>373<\/b>: 30-5.","DOI":"10.1016\/j.bbrc.2008.05.165"},{"key":"65","doi-asserted-by":"crossref","unstructured":"65) Ohsawa I, Ishikawa M, Takahashi K, et al. Hydrogen acts as a therapeutic antioxidant by selectively reducing cytotoxic oxygen radicals. Nat Med 2007; <b>13<\/b>: 688-94.","DOI":"10.1038\/nm1577"},{"key":"66","doi-asserted-by":"crossref","unstructured":"66) Guan WJ, Wei CH, Chen AL, et al. Hydrogen\/oxygen mixed gas inhalation improves disease severity and dyspnea in patients with coronavirus disease 2019 in a recent multicenter, open-label clinical trial. J Thorac Dis 2020; <b>12<\/b>: 3448-52.","DOI":"10.21037\/jtd-2020-057"},{"key":"67","doi-asserted-by":"crossref","unstructured":"67) Shirakawa K, Kobayashi E, Ichihara G, et al. H(2) inhibits the formation of neutrophil extracellular traps. JACC Basic Transl Sci 2022; <b>7<\/b>: 146-61.","DOI":"10.1016\/j.jacbts.2021.11.005"},{"key":"68","doi-asserted-by":"crossref","unstructured":"68) Tamura T, Sano M, Matsuoka T, et al. Hydrogen gas inhalation attenuates endothelial glycocalyx damage and stabilizes hemodynamics in a rat hemorrhagic shock model. Shock 2020; <b>54<\/b>: 377-85.","DOI":"10.1097\/SHK.0000000000001459"}],"container-title":["Annals of Vascular Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/avd\/16\/1\/16_ra.23-00003\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,3,25]],"date-time":"2023-03-25T04:31:29Z","timestamp":1679718689000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/avd\/16\/1\/16_ra.23-00003\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,3,25]]},"references-count":68,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2023]]}},"URL":"https:\/\/doi.org\/10.3400\/avd.ra.23-00003","relation":{},"ISSN":["1881-641X","1881-6428"],"issn-type":[{"value":"1881-641X","type":"print"},{"value":"1881-6428","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,3,25]]},"article-number":"ra.23-00003"}}